ABUS — Arbutus Biopharma Share Price
0.000.00%
Last trade - 00:00- $599.48m
- $486.77m
- $6.17m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.57 | ||
| Price to Tang. Book | 7.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 93.62 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -84.71% | ||
| Return on Equity | -79.02% | ||
| Operating Margin | -1290.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.91 | 10.99 | 39.02 | 18.14 | 6.17 | 6.25 | 4.42 | 0.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
Directors
- Frank Torti NEC (42)
- William Collier PRE (61)
- David Hastings CFO (59)
- Elizabeth Howard EVP (67)
- Michael Sofia CSO (63)
- Michael McElhaugh OTH (47)
- Gaston Picchio OTH (58)
- Daniel Burgess IND (59)
- Andrew Cheng IND (54)
- Richard Henriques IND (65)
- Keith Manchester IND (52)
- James Meyers IND (55)
- Tram Tran IND
- Eric Venker IND (34)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- December 31st, 2017
- Public Since
- November 13th, 2010
- No. of Shareholders
- 102
- No. of Employees
- 44
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 191,527,129
- Address
- 701 Veterans Circle, WARMINSTER, 18974
- Web
- https://www.arbutusbio.com/
- Phone
- +1 2674690914
- Auditors
- Ernst & Young LLP
Upcoming Events for ABUS
Q3 2025 Arbutus Biopharma Corp Earnings Release
Similar to ABUS
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Arbutus Biopharma share price?
As of Today at 19:19 UTC, shares in Arbutus Biopharma are trading at $3.13. This share price information is delayed by 15 minutes.
How has the Arbutus Biopharma share price performed this year?
Shares in Arbutus Biopharma last closed at $3.13 and the price had moved by +0.97% over the past 365 days. In terms of relative price strength the Arbutus Biopharma share price has underperformed the S&P500 Index by -10.69% over the past year.
What are the analyst and broker recommendations for Arbutus Biopharma?
The overall consensus recommendation for Arbutus Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Arbutus Biopharma dividend yield?
Arbutus Biopharma does not currently pay a dividend.
Does Arbutus Biopharma pay a dividend?
Arbutus Biopharma does not currently pay a dividend.
When does Arbutus Biopharma next pay dividends?
Arbutus Biopharma does not currently pay a dividend.
How do I buy Arbutus Biopharma shares?
To buy shares in Arbutus Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Arbutus Biopharma?
As of the previous close price of $3.13, shares in Arbutus Biopharma had a market capitalisation of $599.48m.
Where are Arbutus Biopharma shares listed?
Here are the trading details for Arbutus Biopharma:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ABUS
What kind of share is Arbutus Biopharma?
Based on an overall assessment of its quality, value and momentum Arbutus Biopharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Arbutus Biopharma share price forecast for 2025?
The analyst consensus target price for shares in Arbutus Biopharma is $5.25. That is 67.73% above the last closing price of $3.13.
Analysts covering Arbutus Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.27 for the next financial year.
Find out moreWhat is the trend in the Arbutus Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arbutus Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -6.7%.
As of the last closing price of $3.13, shares in Arbutus Biopharma were trading -10.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Arbutus Biopharma PE Ratio?
The Arbutus Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Arbutus Biopharma?
Arbutus Biopharma's management team is headed by:
- Frank Torti - NEC
- William Collier - PRE
- David Hastings - CFO
- Elizabeth Howard - EVP
- Michael Sofia - CSO
- Michael McElhaugh - OTH
- Gaston Picchio - OTH
- Daniel Burgess - IND
- Andrew Cheng - IND
- Richard Henriques - IND
- Keith Manchester - IND
- James Meyers - IND
- Tram Tran - IND
- Eric Venker - IND